|Phase of Study:||Phase I|
|Treatment Agents:||T cell therapy|
|Treatment Location:||Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions|
|Estimated Length of Stay in Houston:||NA|
|Supported By:||CLL Global Research Foundation|
|Return Visit:||Patients who receive alemtuzumab based therapy may have to come back every 2 |
weeks till the alemtuzumab levels become undetectable.
All patients will come back for follow up at 30, 90 days and 1 year after the
infusion of T cells.